To place any family notices visit bit.ly/HTnotices, or to view visit bit.ly/HTannoucements. We publish tributes (obituaries) free. Fill in this simple online form: https://bit.ly/HTtribute ALLDAY John Peacefully at home on February 2nd, 2021, aged 87 years. Loving Husband to Dorothy, devoted Dad to Elaine, Judy and Russell. Loving Grandad and Great Grandad. Due to the current restrictions a private Funeral Service will take place at Hereford Crematorium on Friday, February 19th at 1.30 p.m. Anyone wishing to pay their respects to John can do so by lining the Crematorium grounds. Family flowers only please, donations if desired in memory of John are for St Michael’s Hospice, these can be sent directly to the charity. All enquires to Shayne Hogg Funeral Services, 72 Whitecross Road, Hereford HR4 0DG. Tel 01432 341871.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China .
Apollomics, Inc.February 12, 2021 GMT
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR™ technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by T
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
TYG100 utilizes proprietary S-TIR(TM) technology platform enabling specific B cell and T cell responses against tumor antigens
Foster City, CA & Hangzhou, CH, Feb 12, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by TYG oncology
Combo Disappoints in Metastatic Prostate Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.